Chemically synthesized semaglutide HD1916 matches Wegovy in Chinese Phase III obesity trial
Mean weight loss was 13.1% with HD1916 versus 14.4% with reference semaglutide at week 44, within the prespecified equivalence margin of plus or minus 4.16%.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 6 20:00 ETSource: Diabetes, obesity & metabolism
The wire
- 01The open-label Phase III trial randomized 462 adults with BMI of at least 28 kg/m2 and no diabetes across 30 Chinese centers to once-weekly HD1916 or semaglutide for 44 weeks.
- 02A chemically synthesized semaglutide that meets equivalence standards points to additional non-Novo supply of the molecule in China, relevant to pricing and access watchers.
- 03Treatment-emergent adverse events occurred in 86.5% versus 89.2% of participants, mostly Grade 1-2; the trial was open-label and limited to a Chinese population without diabetes.
From the source
Read at pubmed.ncbi.nlm.nih.govEfficacy and Safety of Chemically Synthesized Semaglutide Injection (HD1916) for the Treatment of Obesity: A Multicenter, Randomized, Phase III Trial
Diabetes, obesity & metabolism · 2026 Oct 7 · Gao L, Ma Y, Zhang Q et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42839752/
